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Abstract: Primary progressive aphasia (PPA) damages the parts of the brain that control speech
and language. There are three clinical PPA variants: nonfluent/agrammatic (nfvPPA), logopenic
(lvPPA) and semantic (svPPA). The pathophysiology underlying PPA variants is not fully understood, including the role of micro (mi)RNAs which were previously shown to play a role in several
neurodegenerative diseases. Using a two-step analysis (array and validation through real-time
PCR), we investigated the miRNA expression pattern in serum from 54 PPA patients and 18 controls.
In the svPPA cohort, we observed a generalized upregulation of miRNAs with miR-106b-5p and
miR-133a-3p reaching statistical significance (miR-106b-5p: 2.69 ± 0.89 mean ± SD vs. 1.18 ± 0.28,
p < 0.0001; miR-133a-3p: 2.09 ± 0.10 vs. 0.74 ± 0.11 mean ± SD, p = 0.0002). Conversely, in lvPPA,
the majority of miRNAs were downregulated. GO enrichment and KEGG pathway analyses revealed
that target genes of both miRNAs are involved in pathways potentially relevant for the pathogenesis
of neurodegenerative diseases. This is the first study that investigates the expression profile of
circulating miRNAs in PPA variant patients. We identified a specific miRNA expression profile in
svPPA that could differentiate this pathological condition from other PPA variants. Nevertheless,
these preliminary results need to be confirmed in a larger independent cohort.
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1. Introduction
The term primary progressive aphasia (PPA) refers to a diverse group of dementias that
present prominent and early problems with speech and language, often occurring before
the age of sixty-five. The current diagnostic criteria [1] recognize three clinical-anatomical
syndromes of PPA: nonfluent/agrammatic variant PPA (nfvPPA), logopenic variant PPA
(lvPPA) and semantic variant PPA (svPPA), each of which is characterized by specific
linguistic deficits and different neuroanatomical involvement. The syndromes nfvPPA
and svPPA are classified as frontotemporal dementia (FTD) syndromes because of their
propensity to affect the frontal and temporal lobes, respectively, and their association with
frontotemporal lobar degeneration (FTLD) pathology, whereas lvPPA is most commonly
viewed as an atypical variant of Alzheimer’s disease (AD) [1,2]. The major histopathological
associations differ between the major PPA syndromes: nfvPPA is most associated with
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FTLD tauopathies, svPPA is closely associated with TDP-43 pathology and lvPPA with
amyloid deposition, even if there is not complete concordance between phenotypes and
pathology [3]. Based on histopathology, the accumulation of TDP-43 in the brain cortex is
classified into five types, type A through E, depending on the forms of TDP-43 accumulation
in the cerebral cortex. Type A pathology is frequently observed in FTD and nfvPPA. Type B
pathology occurs in FTLD with Amyotrophic Lateral Sclerosis (ALS) and ALS with lesions
that extend to the cerebral cortex. Type C pathology is mainly associated with svPPA [4,5].
A lack of understanding of the underlying pathophysiology, along with the difficulties
of clinical differentiation of PPA variants, makes the diagnostic procedures rather challenging [3,6]. Excluding off-label cholinomimetics for lvPPA (with positive AD biomarkers),
no disease-modifying treatments for PPA variants exist [7]. In the framework of precision
medicine, the lack of disease modification approaches emphasized the need to discover useful molecular biomarkers, not only to improve the prediction of molecular pathology, but
also to monitor the variant specific response to treatment. In this scenario, micro (mi)RNAs
have been considered as key regulators of pathogenesis of several neurodegenerative
diseases [8]. miRNAs are single-stranded, non-coding small RNAs that are abundant in
plants and animals and are conserved across species. The raw transcripts undergo several
nuclear and cytoplasmic post-translation processing steps to generate mature, functional
miRNAs. In the cytoplasm, mature miRNAs associate with other proteins to form the
RNA-induced silencing complex (RISC), enabling the miRNA to imperfectly pair with
cognate miRNA transcripts. The target mRNA is then degraded by the RISC, preventing its translation into protein. miRNA-mediated repression of translation is involved in
many cellular processes, such as differentiation, proliferation and apoptosis, as well as
other key cellular mechanisms [9]. It is now well established that altered RNA processing
could act as a contributing factor to several neurological conditions including aging-related
neurodegenerative diseases such as AD, FTD, ALS and Parkinson’s disease (PD) [10]. For
instance, in AD, the implication of miRNAs in Aβ production, via BACE1 modulation, and
in tau phosphorylation that leads to hyperphosphorylated neurofibrillary tangle formation,
has been demonstrated [9]. Altered miRNA signatures were also identified in AD and
FTD. In particular, several miRNAs have been identified and differentially expressed in
postmortem tissue, blood, and cerebrospinal fluid (CSF) that differ by disease stage [11].
Since miRNAs are able to circulate freely in blood and other body fluids, they are proposed
as possible useful biomarkers for several neurodegenerative diseases such as AD [12],
PD [8] and multiple sclerosis (MS) [13]. Currently, there are few studies regarding miRNAs’
role in FTD, particularly regarding PPA variants as pathogenic modulators as well as
biomarkers [14–16].
Herein, we performed an exploratory study of circulating miRNAs in serum from wellcharacterized PPA variant patients in order to discover possible miRNA signatures and be
able to differentiate among PPA variants and/or identify possible new peripheral biomarkers.
2. Results
The expression profile of 84 miRNAs was performed in a discovery cohort consisting
of 6 svPPA patients, 6 lvPPA, 6 nfv PPA and 6 healthy controls. The volcano plot showed
a generalized upregulation of serum miRNAs in svPPA patients compared with healthy
subjects (Figure 1A). The statistical analysis led to the identification of two significant
upregulated miRNAs: miR-106b-5p (+7.5-fold regulation over controls, p = 0.0027) and
hsa-miR-133a-3p (+22.5-fold regulation over controls, p = 0.000241). Upregulation of these
two miRNAs were subsequently confirmed by Taqman qRT-PCR assays in a validation
cohort composed of 12 svPPA, 12 lvPPA, 12 nfvPPA patients and 12 healthy controls,
confirming previous data (miR-106b-5p: 2.69 ± 0.89 mean ± SD vs. 1.18 ± 0.28, p < 0.0001;
miR-133a-3p: 2.09 ± 0.10 vs. 0.74 ± 0.11 mean ± SD, p = 0.0002, Figure 1B). No differences
were observed stratifying data according to gender and age at onset.
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In nfvPPA and lvPPA patients, deregulation of serum miRNAs expression was observed (Figure 3A,B), although the statistical threshold was not reached. In particular, in
lvPPA patients miR-122-5p, miR-21-5p, miR-223-3p, miR-25-3p, miR-22-3p and miR-24-3p
showed a strong downregulation (−41-, −18-, −6.54-, −22- and −5.71-fold regulation
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Table 1. Characteristics of PPA patients and controls.
Nonfluent/Agrammatic PPA
(n = 18)

Logopenic PPA
(n = 18)

Semantic Variant PPA
(n = 18)

Healthy Controls
(n = 18)

gender (M:F)

6:12

8:10

9:9

10:8

Aβ42 (pg/mL; mean ± SD)

723.6 ± 170.59 *

571 ± 433.7 **

893.15 ± 325.6 ***

1054.54 ± 252

tau (pg/mL; mean ± SD)

491.4 ± 177.50

456.4 ± 177.9

338.15 ± 170.2

380 ± 274

p-tau (pg/mL; mean ± SD)

55.6 ± 25.88

61.4 ± 24.27

49.38 ± 19.05

58 ± 46

mean age (years ± SD)

76.3 ± 8.6

81 ± 8.1

79 ± 9.4

78 ± 7.3

63.5 ± 0.44

70 ± 0.36

64 ± 0.98

mean age at onset (years ± SD)

Presence of AD signature in * 2, ** 8 and *** 2 patients.

svPPA has been consistently associated with TDP-43 type C pathology [23]. Albeit the
dysfunction of TDP-43 has been associated with multiple neurodegenerative diseases, and
the exact pathophysiological mechanisms still need to be elucidated. A common pathologic
hallmark encompassing all the TDP-43 “proteinopathies” is the cytoplasmic aggregation
and nuclear clearance of TDP-43 [24]. This commonality led to the suggestion that nuclear
loss-of-function and cytoplasmic gain-of-function could be at the origin of TDP-43 driven
neurodegeneration [24]. The lack of nuclear TDP-43 determines the deregulation of RNA
synthesis, autophagy and stress granule formation, whereas the pathologic accumulation
of insoluble TDP-43 in the cytoplasm leads to deposit formation and ultimately, neuronal
death. Mitochondrial dysfunction has been proposed as an additional route mediating
TDP-43 pathology [25]. Of note, increased miR-106b-5p, which was significantly upregulated in svPPA, has been associated with the disruption of mitochondrial fusion and
the impairment of oxidative phosphorylation [26]. The over-expression of miRA-106b-5p
levels in people with svPPA could reflect a tentative compensatory mechanism or just the
consequence of mitochondrial damage. Defective microglia clearance of TDP-43 has been
proposed as another possible mechanism underlying TDP-43 accumulation [27]. Interestingly, miR-133a-3p, which was significantly upregulated in our cohort of svPPA, has been
demonstrated to suppress microglia activation in a mouse model of neuropathic pain [27],
potentially favoring TDP-43 accumulation and neurodegeneration. Importantly, several
studies underlie the role of miR-133a-3p in the modulation of inflammation. This miRNA is
involved, for example, in a competing endogenous RNA (ceRNAs) network. The CircHelz
RNA, a circular RNA encoded by helicase with the zinc finger (Helz) gene, promotes the
activation of NLPR3 inflammasome by the inhibition of miR-133a-3p expression [28].
miR-106b-5p and miR-133a-3p have recently been associated with other neurodegenerative diseases and proposed as possible biomarkers underling the fact that they are possibly
important players in cerebral physiopathology. For instance, deregulated miR-106-5p
provided the best discrimination between PD and progressive supranuclear palsy (PSP)
patients [29]. Moreover, a downregulation of circulating miR-106b-5p in MS was found,
and this data is correlated with increased production of neuroprotective brain derived
neurotrophic factor (BDNF) as a compensatory mechanism [30]. Regarding miR-133a-3p, a
possible link between upregulated circulating miRNA levels and ALS patients was found,
even if ALS is associated with TDP-43 type A and/or B, but not C, which is the TDP-43
subtype often associated with svPPA [31,32]. It is important to take into account that a
subset of svPPA cases can present with other pathologies, including AD pathology, which
has been described in up to 25% of svPPA [33,34]. Nevertheless, a recent meta-analysis
showed that amyloid has been detected (via CSF biomarkers, Amyloid PET or autopsy) in
16% of svPPA [17], which is in line with our results (11%).
Our in silico analysis of miRNA pathways showed that 492 mRNA targets are common
between miR-133a-3p and miR-106b-5p, and some of which are involved in neurodegenerative pathways. In this regard, it is worth noting that one of the 492 overlapped mRNAs
targets is the solute carrier family 41 member 1 (SLC41A1). A recent work reported a
rare loss-of-function variant of this gene in a cohort of 80 patients diagnosed with early
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onset of PD, and one of the mechanisms hypothesized behind the loss of function is that
SLC41A1 could influence mitochondrial processes involved in energy production [35,36].
Further, an extensive RNA sequencing study in the frontal cortex tissue of patients with
frontotemporal lobar degeneration revealed a decreased differential expression of the small
integral membrane protein 14 gene (SMIM14) [37]. SMIM14, one of the overlapped mRNAs’ target and between our significantly differential regulated miRNAs, is also associated
with mitochondrial functions [37]. Taking into consideration that miRNAs are implicated
in gene post-transcriptional control and the upregulation of miRNAs can result in the
downregulation of target gene expression, and we can speculate that the upregulation of
miR-133a-3p and miR-106b-5p may downregulate some of the common 39 target mRNAs.
Interestingly, among the 39 common mRNAs targets for miR-133a-3p and miR-106b-5p,
there is a DERL2 gene, encoding for Derlin-2 protein, one of the endoplasmic reticulum (ER)
membrane proteins and part of the ERAD degradation complex which eliminates unfolded
proteins [38]. Recent findings by Sugiyama et al. demonstrated that Derlin-2-deficient mice
have widespread postnatal brain atrophy in the cerebellum and striatum as well as reduced
neurite outgrowth and motor function deficits [39]. We can hypothesize that a generalized
downregulation of miRNAs observed in lvPPA could lead to a translation upregulation
and an alteration of target gene expression [40] and vice-versa in svPPA. However, further
studies are needed to clarify how miRNAs target mRNAs in the molecular pathology
behind svPPA and lvPPA.
Certainly, a limitation of this study is the small size of the cohort analyzed, which
can influence the significance threshold. Therefore, further analyses of miRNA strongly
up- or downregulated would be needed, and possibly in comparison to AD. Nevertheless,
data obtained in svPPA in such a small cohort suggest that the upregulation of miRNA is
actually remarkable in these patients, and the mechanisms at the basis of these observations
need to be better studied.
In conclusion, we showed that there is a specific miRNA expression profile in svPPA
that differentiates this pathological condition from other PPA variants, and in particular
from lvPPA. miR-133a-3p and miR-106b-3p are significantly upregulated in svPPA and
also in the validation cohort, but these preliminary results need to be confirmed in a larger
independent cohort.
4. Materials and Methods
4.1. Population
Seventy-two subjects (18 svPPA, 18 lvPPA, 18 nfvPPA and 18 healthy controls) were
recruited at the Alzheimer Unit of the Fondazione Cà Granda, IRCCS Ospedale Maggiore
Policlinico, University of Milan (Milan). All patients underwent a standard battery of
examinations, including their medical history, a physical and neurological examination,
laboratory screening tests, neurocognitive evaluation and imaging. The Clinical Dementia
Rating (CDR), the Mini Mental State Examination (MMSE), the Frontal Assessment Battery
(FAB), the Wisconsin Card Sorting Test (WCST), and the Tower of London test assessed
cognitive dysfunctions. The presence of significant vascular brain damage was excluded
(Hachinski Ischemic Score < 4). Lumbar punctures were performed after one night of
fasting. The PPA patients were diagnosed according to current consensus criteria [1]. All
PPA patients were screened for possible mutations in MAPT, GRN and C9ORF72 genes.
The control group consisted of 18 non-demented volunteers matched for ethnic background
and age and without memory and psycho-behavioral dysfunctions (MMSE ≥ 28). Informed
consent to participate in this study was given by all subjects or their caregivers. The study
protocol had been previously approved by the local Institutional Review Board.
The characteristics of patients and controls are summarized in Table 1.
4.2. Serum Sample Collection
Whole blood samples were allowed to sit at room temperature for a minimum of
30 min and a max of 2 h after collection. Separation of the clot was done by centrifugation
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at 10 min 1300× g at room temperature for 15–20 min. The serum samples were removed
and dispensed in aliquots of 400 µL and put into cryotubes. Specimens were stored at
−80 ◦ C until used.
4.3. AD CSF Biomarkers Measurement
CSF samples were collected into 15 mL polypropylene tubes by LP in the L3/L4 or
L4/L5 interspace. The samples were centrifuged at 2000 r/min for 10 min at 4 ◦ C. The
supernatants were stored at −80 ◦ C until used. CSF Aβ, tau and Ptau were measured
with ELISA kits (Fujirebio, Ghent, Belgium). The normal values of biomarkers were:
Aβ > 600 pg/mL; tau < 400 pg/mL and Ptau < 61 pg/mL [41].
4.4. miRNA Isolation from Human Serum Samples
200 µL of human serum was thawed on ice and lysed with 1.5 volume of Qiazol
(Qiagen, Hilden, Germany). To allow sample-to-sample normalization, synthetic C. elegans
miRNA cel-miR-39 (Qiagen) was added (as a mixture of 25 fmol of each oligonucleotide in
5 µL total volume) to each denatured sample. RNA was isolated using miReasy Mini Kit,
following the manufacturer’s protocol for liquid samples (Qiagen) [12].
4.5. Screening of miRNAs in Human Serum by Human Serum & Plasma miScript miRNA
PCR Array
RNA was retro-transcribed with miScript II RT kit (Qiagen), according to the instructions of the manufacturer. For real-time PCR experiments, the Human Serum & Plasma
miScript miRNA PCR Array (MIHS-106ZC) was used, and runs were performed in a
QuantStudio 12K system. The array profiles the expression of 84 of the most abundantly
expressed and best characterized miRNA sequences in serum, plasma and other body
fluids. These arrays included short non-coding RNAs (SNORD61, SNORD68, SNORD72,
SNORD95, SNORD96A and RNU6B-2) for the proper normalization of the data, miRNA
reverse transcription control and a positive PCR control.
4.6. Validation of Best Hits by Taqman qRT-PCR Assays
3 µL of RNA was reverse transcribed using the TaqMan miRNA Reverse Transcription
Kit and miRNA-specific stem-loop primers (ThermoFisher Scientific, Waltham, MA, USA)
in a small-scale RT reaction. 0.8 µL of RT product was used for qRT-PCR and was run on
QuantStudio 12K using specific TaqMan miRNA assays (ThemoFisher Scientific) [12].
4.7. Target Gene Prediction and Bioinformatics Analysis
Target genes of two candidate miRNAs were predicted using online bioinformatic
tools; TargetScan 7.0 (available online: http://www.targetscan.org, accessed on 14 July
2022) and miRDB (available online: http:/www.mirdb.org, accessed on 14 July 2022). Venn
diagrams (available online: http:/bioinformatics.psb.urgent.be/webtools/Venn, accessed
on 14 July 2022) were used to obtain overlapping target genes from the two bioinformatic
tools. GO enrichment analyses of biological processes (BP), cellular component (CC), molecular function (MF), Kyoto Encyclopedia of Genes and Genomes (KEGG) and interactome
pathways were obtained using the DAVID (available online: http://david.ncifcrf.gov,
accessed on 14 July 2022) bioinformatics tool [42]. A false discovery rate (FDR) < 0.05 was
used as the cut-off criteria.
4.8. Statistical Analysis
The Qiagen PCR Array data analysis was based on ∆∆Ct method with normalization
of the raw data to housekeeping genes (using the software available at http://www.
sabiosciences.com/pcarraydataanalysis.php, accessed on 1 June 2022). p values were
calculated based on a student’s t-test of the replicate 2ˆ(−Delta Ct) values for each gene in
the control and PPA groups. Best hits were chosen based on statistical significance (p < 0.05).
Data distribution was tested for normality with the Kolmogorov–Smirnov and Shapiro–
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Wilk Test. All data are shown as mean ± SD. The differences between the three groups
were analyzed with One-Way ANOVA followed by Tukey’s test as multiple comparison
post hoc. Receiver-operating-characteristic (ROC) curves were generated and areas under
the curves (AUCs) were calculated as well as specificities for fixed sensitivity values with
corresponding 95% confidence intervals (CI). For statistical analysis, GraphPad Prism 9.0
(La Jolla, CA, USA) software was used.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/ijms23158487/s1.
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